Following Presentation by AB Science

(Boursier.com) — AB Science will hold a virtual conference on its microtubule destabilizer platform on Thursday, March 16, from 6 p.m. to 7 p.m., to present the ongoing phase 1/2 with AB8939 as well as its synthetic microtubule destabilizer platform.

During the virtual conference, AB Science will present:
– The pharmacological properties of AB8939 and its main differentiating factors
– The therapeutic potential of AB8939, demonstrated by a series of preclinical studies
– The ongoing phase 1/2 study and the 1st case report from the initial phase of this study

The following people will participate in the virtual conference:
– Alain Moussy, co-founder and president of AB Science
– Olivier Hermine, MD, PhD, Head of the Hematology Department at Necker-Enfants Malades Hospital, Paris, France
– Christian Auclair, PhD, expert in onco-pharmacology
– Laurent Gros, PhD, director of the Drug Discovery department at AB Science

This conference will be followed by a question and answer session with the management of AB Science.